Pangaea Oncology, S.A. (BME:PANG)

Market Cap	56.69M -2.9%
Revenue (ttm)	14.35M +122.3%
Net Income	-5.34M
EPS	-0.18
Shares Out	34.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,450
Average Volume	5,729
Open	1.650
Previous Close	1.650
Day's Range	1.650 - 1.650
52-Week Range	1.630 - 1.750
Beta	0.08
RSI	40.39
Earnings Date	Apr 28, 2026

About Pangaea Oncology

Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients in Spain and the rest of European Union countries. It offers molecular diagnostics, such as mutation analysis in tissue and liquid biopsy, gene amplification and translocation testing, immunohistochemistry and fluorescence in-situ hybridization, and gene expression profiling; clinical trials; in vitro drug profiling, including MTT proliferation assays, western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx p...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2006
• Employees: 159
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PANG

Financial Performance

In 2023, Pangaea Oncology's revenue was 9.95 million, an increase of 49.12% compared to the previous year's 6.68 million. Losses were -4.66 million, 71.7% more than in 2022.